The DOI matches its Crossref record; the references it cites are not checked yet.
Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 8
Research works printed but not linked: 8
- Wang Y, Li C, Gale RP, Liang Q, Kay NE, Huang Q, et al. Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies. Leukemia. 2026;40:1439–47. · DOI
- Rios-Olais FA, McGary AK, Tsang M, Almader-Douglas D, Leis JF, Buras MR, et al. Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1221–7. · DOI
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. · DOI · Paper page
- Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924–35. · DOI
- Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108–20. · DOI
- Eichhorst B, Niemann CU, Kater AP, Furstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54. · DOI
- Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol. 2023;41:3689–99. · DOI
- Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–63. · DOI · Paper page
Metadata
- Authors
- Fiorica, G., Wehmeyer, G., Yee, C. I., Segovia, D., Rios-Olais, F. A., Hilal, T., & Kittai, A. S.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Tisch Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center (US)
- Corresponding author
- Hilal, Talal
- Venue
- Leukemia
- Published
- 2026-10-22
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W7223177333
- Cited by
- 0
- References
- 8
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- chronic lymphocytic leukemia, minimal residual disease, bone marrow, blood, concordance, first-line therapy, novel agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41375-026-03178-9
- The paper
- Fiorica, G., Wehmeyer, G., Yee, C. I., Segovia, D., Rios-Olais, F. A., Hilal, T., & Kittai, A. S. (2026). Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leukemia. https://doi.org/10.1038/s41375-026-03178-9
